Table 1 Depiction of the fundamental characteristics of the selected articles
Study | Year | Country | Diagnosis | Type | Sample size | Gender (M/F) | Mean age (years) | Child–Pugh(A/B) | Intervention | Follow-up Time (months) | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|
Shuguang Ju [20] | 2021 | China | unresectable HCC | RCT | 52 | 44/8 | 55 | 41/11 | camrelizumab + apatinib | 13.5 | ORR, DCR, mPFS, mOS, AEs |
Guosheng Yuan [25] | 2021 | China | unresectable HCC | A single-arm study | 86 | 72/14 | 55 | 64/22 | camrelizumab + apatinib | NR | ORR, DCR, AEs |
Jianming Xu [21] | 2021 | China | advanced HCC | A single-arm study | 190 | 169/21 | 53 | 162/28 | camrelizumab + apatinib | 16.7 | ORR, mPFS, AEs |
Zhiming Zeng [23] | 2021 | China | advanced liver cancer | A single-arm study | 45 | 35/10 | 52 | 38/7 | camrelizumab + apatinib | NR | ORR, DCR, AEs |
Yongxiang Xia [24] | 2022 | China | HCC | A single-arm study | 18 | 17/1 | 54.7 | NR | camrelizumab + apatinib | NR | ORR, AEs |
Kuimin Mei [22] | 2021 | China | advanced primary liver cancer | A single-arm study | 21 | 18/3 | 48 | 20/1 | camrelizumab + apatinib | 12.4 | ORR, DCR, mOS, mPFS, AEs |
Jianming Xu [19] | 2019 | China | advanced HCC | A single-arm study | 18 | 17/1 | 49 | 13/5 | camrelizumab + apatinib | 7.9 | ORR, DCR mPFS, AEs |
Guosheng Yuan [26] | 2020 | China | HCC | A single-arm study | 63 | 58/5 | 48 | 54/9 | camrelizumab + apatinib | 12.6 | ORR, DCR, mPFS, AEs |
Shukui Qin [27] | 2023 | China | unresectable or metastatic HCC | RCT | 272 | 227/45 | 58 | 236/36 | camrelizumab + apatinib | 14.5 | ORR, mPFS, mOS, AEs |
Dongbo Chen [28] | 2023 | China | HCC | A single-arm study | 86 | 77/9 | 57 | NR | camrelizumab + apatinib | 13.5 | ORR, DCR, mPFS, mOS, AEs |